{
    "clinical_study": {
        "@rank": "139731", 
        "arm_group": [
            {
                "arm_group_label": "ABT-199 after ibrutinib therapy", 
                "arm_group_type": "Experimental", 
                "description": "Single daily doses increasing weekly as tolerated"
            }, 
            {
                "arm_group_label": "ABT-199 after idelalisib therapy", 
                "arm_group_type": "Experimental", 
                "description": "Single daily doses increasing weekly as tolerated"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy\n      and safety of ABT-199 in approximately 40 subjects with relapsed or refractory CLL after\n      B-cell receptor signaling pathway inhibitors (BCR PI) treatment."
        }, 
        "brief_title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop\n             on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL\n             NCI-WG) criteria\n\n          -  Subject has relapsed/refractory disease with an indication for treatment\n\n          -  Subject has refractory disease or developed recurrence after therapy with a BCR PI\n\n          -  Subject must have an Eastern Cooperative Oncology Group performance score of equal to\n             or less than 2\n\n          -  Subject must have adequate bone marrow function at Screening\n\n          -  Subject must have adequate coagulation profile, renal, and hepatic function, per\n             laboratory reference range at Screening\n\n        Exclusion Criteria:\n\n          -  Subject has undergone an allogeneic stem cell transplant within the past year\n\n          -  Subject has developed Richter's transformation confirmed by biopsy\n\n          -  Subject has active and uncontrolled autoimmune cytopenia\n\n          -  Subject has malabsorption syndrome or other condition that precludes enteral route of\n             administration\n\n          -  Subject is  human immunodeficiency virus (HIV) positive or has chronic hepatitis B or\n             hepatitis C virus requiring treatment\n\n          -  Subject has known contraindication or allergy to both xanthine oxidase inhibitors and\n             rasburicase."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141282", 
            "org_study_id": "M14-032", 
            "secondary_id": "2014-000874-20"
        }, 
        "intervention": {
            "arm_group_label": [
                "ABT-199 after ibrutinib therapy", 
                "ABT-199 after idelalisib therapy"
            ], 
            "description": "ABT-199 monotherapy", 
            "intervention_name": "ABT-199", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Receptors, Antigen, B-Cell"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Lymphocytic Leukemia", 
            "Oncology", 
            "Cancer of the blood and bone marrow"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy", 
        "other_outcome": [
            {
                "description": "The number of days from the date of first dose of ABT-199 to the date of first dose of new non-protocol anti-leukemia therapy (NPT) or death from any cause", 
                "measure": "Time to Next Anti-CLL Treatment (TNT)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The presence of less that once CLL cell per 10,000 leukocytes in either peripheral blood and/or bone marrow", 
                "measure": "Rate of minimal residual disease (MRD) negativity status", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }
        ], 
        "overall_contact": {
            "email": "michael.dawson@abbvie.com", 
            "last_name": "Mike  Dawson, BS", 
            "phone": "847-938-9467"
        }, 
        "overall_contact_backup": {
            "email": "kim.burns@abbvie.com", 
            "last_name": "Kim  Burns, BA", 
            "phone": "847-936-1152"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Jalaja   Potluri, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the efficacy of ABT-199 monotherapy in subjects with chronic lymphocytic leukemia (CLL) relapsed or refractory to B-cell Receptor Signaling Pathway Inhibitors. Assessed by the investigator, based on laboratory results, physical examinations, CT scans, and bone marrow examinations", 
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141282"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of days from the date of first response (complete response (CR) or partial response (PR)) to the earliest recurrence or disease progression (PD)", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 2 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The number of days from the date of first dose or enrollment if not dosed to the date of earliest PD", 
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 5 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The number of days from the date of first dose to the date of earliest PD or death", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 5 years after the last subject has enrolled in the study."
            }, 
            {
                "description": "The number of days from the date of first dose to the date of death for all dosed subjects", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Measured up to 5 years after the last subject has enrolled in the study."
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech/Roche", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}